Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $5.8200 (7.98%) ($5.2600 - $6.1300) on Wed. Jul. 22, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.07% (three month average) | RSI | 82 | Latest Price | $5.8200(7.98%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 3.7% a day on average for past five trading days. | Weekly Trend | VBIV advances 29.9% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) ACES(66%) UNG(32%) SIL(27%) XBI(61%) VWO(10%) | Factors Impacting VBIV price | VBIV will decline at least -4.035% in a week (0% probabilities). IPO(-21%) GDXJ(44%) GDX(56%) IBUY(-6%) EEM(18%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -4.035% (StdDev 8.07%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.68(2.46%) | 10 Day Moving Average | $4.99(16.63%) | 20 Day Moving Average | $4.13(40.92%) | To recent high | -5.5% | To recent low | 16.3% | Market Cap | $1.342b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |